EMA Recommends Granting a Marketing Authorisation for Lurbinectedin By Ogkologos - April 30, 2026 232 0 Facebook Twitter Google+ Pinterest WhatsApp It is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR The path to least resistance: How our researchers are outsmarting cancer’s... May 25, 2022 Expression of AR-regulated Genes in CTCs Is Prognostic for Survival and... July 7, 2021 Attorney Donates $30K In Gift Cards So Parents Can Purchase Gifts... December 17, 2021 EMA Recommends Extension of Therapeutic Indications for Atezolizumab May 24, 2022 Load more HOT NEWS HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in... Dad Sings “Ave Maria” For His Daughter At Disney World Venetoclax-Obinutuzumab With or Without Ibrutinib Is Superior to Chemoimmunotherapy in First-Line... New on NCI’s Websites for April 2024
